3.2 Conceptualización de las variables de investigación
3.2.5 El Burnout y la relación con la personalidad
Based on findings from this study, these are the recommendations.
The use blood levels of therapeutic drugs levels in assessing seizure control, drug
adherence and adverse effects should be interpreted with caution and judgements should be based on both clinical and individual characteristics rather than absolute drug levels.
It may be necessary to conduct further studies in this environment to determine the therapeutic and toxic range of carbamazepine in Nigerian patients with epilepsy.
It may be necessary to establish individual therapeutic levels in patients with epilepsy thus providing a baseline for comparison when assessing seizure control and drug adherence in relation to drug levels.
The study showed that higher levels of carbamazepine does not necessarily improve seizure control therefore further studies need to be done to determine if this result is reproducible and if similar, optimal dose of carbamazepine should be determined.
A single measurement of drug levels level may not be a good method to assess drug adherence in patients considering the half-life of carbamazepine. Other measures of long term adherence should be explored.
References
1. Fisher RS, Boas WVE, Blume W, Elger C, Genton P, Lee P et al. Epileptic seizures and epilepsy: definitions proposed by the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46:470–472.
2. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross H, Elger CE et al. A practical clinical definition of epilepsy Epilepsia 2014; 55(4):475–48.
3. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: A meta-analytic approach. Epilepsia.
2010;51:883–90
4. Epilepsy Fact sheet N°999 World Health Organisation 2014 [Cited 2014 August 8].
Available from http://www.who.int/mediacentre/factsheets/fs999/en/index.htm 5.
Sander JW. The Use of Antiepileptic Drugs—Principles and Practice. Epilepsia 2004;
45(6): 28–34.
6. Danesi MA. Epilepsy in adolescent school children in a developing country: A clinical and social analysis. International Journal of Adolescent Medicine and Health. 1989; 4(2): 99–112.
7. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the sub commission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;
49(7):1239–1276.
8. Kiran D, Piyush B, Veena SG, Ghalaut PS. Therapeutic drug monitoring for antiepileptic drugs using HPLC: An experience at a tertiary care hospital in India
Neurology Asia 2010; 15(3): 233 – 237.
9. Shweta S, Sushma M, Surekha J, Renuka K, Urmila T. Comparison of Salivary versus Serum Carbamazepine and Phenytoin Levels in Epileptic Children.
Bombay Hospital Journal. 2008; 50(4):572-576.
10. Adherence to long term therapies; evidence for action. WHO 2003.[cited 2014 August
8]. Available from http://whqlibdoc.who.int/publications/2003/9241545992.pdf.
11. Elechi CA. Default and non-compliance among adult epileptics in Zaria, Nigeria. The need to restructure continued care. Tropical geographical medicine 1991;43(1-2):242-
5.
12. Wendy GM, Lawrence MS, and Sherryl AB. Adherence to Treatment in Children with
Epilepsy: Who Follows “Doctor’s Orders”? Epilepsia. 2000; 41(12):1616–1625.
13. Bromfield EB, Cavazos JE, Sirven JI. Neuropharmacology of antiepileptic drugs. In: An Introduction to Epilepsy.West Hartford (CT): American Epilepsy Society; 2006.
[cited 2014 Aug. 8] Available from http:// www. ncbi.nlm.nih .gov/books/NBK2513/#
A908
14. Rowan AJ, Ramsay RE, Collins JF, Pryor F. New onset geriatric epilepsy. A randomized study of gabapentin, lamotrigine, and carbamazepine.
Neurology
2005;64(11):1868-1873 15. Epilepsy Facts.
http://www.who.int/mental_health/neurology/epilepsy/en/index.html 6/6/2011.
16. Sridharan R. Epidemiology of epilepsy. Current Science, 2002; 82(6): 664-670.
17. Epilepsy foundation. Incidence and Prevalence. [homepage on the internet].
Patricia O. Shafer, Joseph I. Sirven : Epilepsy Foundation. [updated 2014 March] Available from
http://www.epilepsyfoundation.org/aboutepilepsy/whatisepilepsy/statistics .cfm.
18. Commission on Epidemiology and Prognosis: International League against Epilepsy.
Guidelines for Epidemiologic Studies on Epilepsy. Epilepsia. 1993; 34:592–596.
19. Danesi, M.A., Odusote, K.A.,Roberts, O.O, Adu, O.E. Social problems of Adolescent and Adult epileptics in a Developing country, as seen in Lagos, Nigeria. Epilepsia, 1981; 22: 689-96.
20. Shamansky, S.L. and Glaser, G.H.: Socioeconomic characteristics of seizure disorders. Epilepsia, 1979; 20: 457-74
21. Paul A, Adeloye D, George-Carey R, Kolčić I, Grant L and Chan KY. An estimate of the prevalence of epilepsy in Sub–Saharan Africa: A systematic analysis. J Glob Health
2012; 2(2): 020405.
22. Preux PM, Druet-Cabanaca M. Epidemiology and aetiology of epilepsy in sub-
Saharan Africa. The Lancet Neurology 2005; 4(1):21 – 31.
23. Ogunrin O.O. Epilepsy in Nigeria – A review of etiology, epidemiology and management.Benin Journal of Postgraduate Medicine 2006; 8(1):27-51.
24. Tellez-zenteno JF, Pondal-Sordo M, Martijevic S and Wiebe S. National and Regional
Prevalence of Self-reported Epilepsy in Canada. Epilepsia 2004; 45 (12):1626-1629.
25. Picot MC, Baldy-Moulinier M, Daurès JP, Dujols P, Crespel A. The prevalence of epilepsy and Pharmacoresistant Epilepsy in Adults: A population-based study in a Western European country. Epilepsia 2008; 49 (7):1230-1238.
26. Wang WZ, Wu JZ, Wang DS, Dai XY, Yang B, Wang TP et al. The prevalence and treatment gap in epilepsy in China: an ILAE/IBE/WHO study. Neurology 2003; 60(9):1544-5.
27. Ray BK, Bhattacharya S, Kundu TN, Saha SP, Das SK. Epidemiology of epilepsy-
Indian perspective. J. Indian Medical Association. 2002; 100(5):322-6.
28. Senanayake, N and Roman, G.C.: Epidemiology of epilepsy in developing countries.
Bull. World Health Organisation, 1993; 71(2): 247-58.
29. Gracia,F, de Lao SL, Castillo L, Larreategui M, Archbold C, Brenes MM, et al.
Epidemiology of epilepsy in Guaymi Indians from Bocas del Toro Province, Republic of Panama.Epilepsia. Epilepsia 1990; 31:718-723.
30. World Health Organization. Epilepsy in the WHO African region: Bridging the gap. Brazzaville: WHO, 2004. [Cited 2014 Aug.8]. Available from
http://www.who.int/mental_health/management/epilepsy_in_African-region.pdf
31. Aall-Jilek, L.M. Epilepsy in the Wapogoro tribe in Tanganyika. Acta Psychiatrica
Scandinavica, 1965; 41: 57-86.
32. Goudsmit, J, van der Waals FW, Gajdusek D. Epilepsy in the Gbawein and Wroughbarh clan of Grand Bassa County, Liberia: the endemic occurrence of
"Seeee" in the native population. Neuroepidemiology, 1983; 2: 24-34.
33. Reynolds, E.H.: Historical aspects in 'Epilepsy, Behaviour and Cognitive Function',
1988; John Wiley Medical Publication. Pp. 3-8. (Trimble, M.R and Reynolds E.W.
ed).
34. Dada, T.O. Epilepsy in Lagos, Nigeria. African Journal of Medical Sciences, 1970; 1:
161-84.
35. Osuntokun BO, Adeuja AO, Schoenberg BS, Bademosi O, Nottidge VA, Olumide AO, Lge O et al. Prevalence of the epilepsies in Nigerian Africans: a communitybased study. Epilepsia 1987; 28: 272–79.
36. Osuntokun B.O., Schoenberg B. S., Nottidgec V.A., Adeujaa A., Bademosia. O.
et al.
Research for Measuring the Prevalence of Neurologic Disorders in Developing Countries. Results of a Pilot Study in Nigeria. Neuroepidemiology 1982; 1:143-153.
37. Longe AC, Osuntokun BO. Prevalence of neurological disorders in Udo, a rural community in Southern Nigeria. Trop Geographical Med. 1989; 41: 36–
40.
38. Nwani P O, Asomugha LA, Arinze EO, Ewereji KO, Nwosu MC, Ogunniyi A.
Patterns of antiepileptic drug use and seizure control among people with epilepsy in a suburban community in southeast Nigeria. African journal of neurological sciences
2012 ; 31(2)
39. Vestergaard M, Pedersen CB, Sidenius P, Olsen J and Christensen J. The Long-Term Risk of Epilepsy after Febrile Seizures in Susceptible Subgroups.
American Journal of Epidemiology. 2007; 165(8): 911-918.
40. Obembe, A. and Ahmed, M.H. Epilepsy in Kaduna: A study of 164 Youths. Nig.
Med. Pract., 1988: 16(2); 45-8.
41. Danesi, M.A.: Classification of the epilepsies: An investigation of 945 patients in a developing country. Epilepsia, 1985: 26(2): 131-36 42. Ogunrin OA, Adeyekun AA Profile of post-traumatic epilepsy in Benin City,
Nigeria.
West African journal of medicine.2010; 29(3):153-7.
43. Shorvon S, Duncan J, Koepp M, Sander J, Smith S, Walker M. Epilepsy and Related
Disorders. In: Clarke C, Howard R, Rossor M and Shorvon S, editors. Neurology A Queen Square Textbook Neurology. First edition. Blackwell Publishing Ltd. 2009. p.
189-243.
44. Lindsten H, Stenlund H and Forsgren L. Remission of Seizures in a Population-Based Adult Cohort with a Newly Diagnosed Unprovoked Epileptic Seizure. Epilepsia 2001; 42: 1025–1030.
45. Nicoletti A, Sofia V, Vitale G, Bonelli SI, Bejarano V, Bartalesi F et al. A.
Natural History and Mortality of Chronic Epilepsy in an Untreated Population of Rural
Bolivia: A Follow-Up after 10 years. Epilepsia. 2009; 50(10):2199–2206.
46. Ogunniyi A, Oluwole OS, Osuntokun BO. Two-year remission in Nigerian epileptics.
East African Journal of Medicine. 1998; 75(7):392-5.
47. Verma A, Misra S. Risk of seizure recurrence after antiepileptic drug withdrawal, an
Indian study. Neurology Asia 2006; 11: 19 – 23.
48. Atlas: Epilepsy care in the world. WHO 2005. [Cited 2014 August 12].
Available from
http://www.who.int/mental_health/neurology/Epilepsy_services2_rev1.pdf .
49. Cohen-Gadol AA, Wilhelmi BG, Collignon F, White JB, Britton JW, Cambier DM et al. Long-term outcome of epilepsy surgery among 399 patients with nonlesional seizure foci including mesial temporal lobe sclerosis. J
Neurosurg 2006; 104(4):513-
24.
50. Fong JS, Jehi L, Najm I, Prayson RA, Busch R, Bingaman W. Seizure outcome and its predictors after temporal lobe epilepsy surgery in patients with normal MRI.
Epilepsia 2011; 52(8):1393-401.
51. Baker GA, Brooks J, Buck D and Jacoby A. The Stigma of Epilepsy: A European Perspective. Epilepsia 2000; 41: 98–104.
52. Al-khateeb J.M, Al-khateeb A.J. Research on psychosocial aspects of epilepsy in Arab countries: A review of literature. Epilepsy and behaviour 2014;
.31:256-262.
53. Ndoye NF, Sow A.D, Diop, A.G, Sessouma. B, Sene- Diouf .F, Boissy .L et al.
Prevalence of epilepsy its treatment, gap and knowledge, attitude and practice of its population in sub-urban Senegal, an ILAE/IBE/WHO study.
Seizures 2005;
14(2):106-111.
54. Kabir M, Iliyasu.Z, Abubakar S, Kabir S and Farinyaro U. Knowledge, attitude and beliefs about epilepsy among adults in a northern Nigerian urban community. Annals of African Medicine Vol. 4, No. 3; 2005: 107 – 112
55. Forsgren L, Hauser WA, Olafsson E, Sander JW, Sillanpää M and Tomson T.
Mortality of epilepsy in developed countries: a review. Epilepsia 2005; 46 (11):18-
27.
56. Cockerell, O. C., Johnson, A. L., Sander, J. W. A. S., Hart,Y. M., Goodridge, D.
M. and Shorvon, S. D., Mortality from epilepsy: results from a prospective populationbased study. Lancet 1994; 344:918–921.
57. Sander, J. W. and Hart, Y. M., Epilepsy Questions and Answers, Merit Publishing,
Hampshire, 1999, pp. 43–49.
58. Andrea S Winkler. Measuring the epilepsy treatment gap in sub-Saharan Africa. The
Lancet Neurology 2012; 11(8): 655 – 657.
59. Sidenvall R, Forsgren L, Heijbel J. Prevalence and characteristics of epilepsy in children in northern Sweden. Seizure 1996;5: 139–46.
60. Haerer AF, Anderson DW, Schoenberg BS. Prevalence and clinical features of epilepsy in a biracial United States population. Epilepsia 1986;27: 66–75.
61. Mbuba CK, Ngugi AK, Fegan G, Ibinda F, Muchohi SN. Nyundo C et al. Risk factors associated with the epilepsy treatment gap in Kilfi, Kenya: a cross-sectional study.
Lancet Neurol 2012; 11(8):688-96.
62. Meyer AC1, Dua T, Boscardin WJ, Escarce JJ, Saxena S, Birbeck GL, Critical determinants of the epilepsy treatment gap: a cross-national analysis in resourcelimited settings.. Epilepsia 2012 Dec;53(12):2178-85. doi:
10.1111/epi.12002. Epub 2012 Oct 25.
63. Danesi M.A and Adetunji J.B. Use of alternative medicine by patients with epilepsy; a survey of 265 patients in a developing country. Epilepsia 1994;
35:344-351.
64. Ogunrin OA, Adeyekun A, Adudu P. Etiologies of epilepsy and health-seeking itinerary of patients with epilepsy in a resource poor setting: analysis of 342 Nigerian
Africans. Seizure. 2013; 22(7):572-6.
65. Bromfield EB, Cavazos JE, Sirven JI. Neuropharmacology of antiepileptic drugs. In:
An Introduction to Epilepsy.West Hartford (CT): American Epilepsy Society; 2006.
[cited 2014 Aug. 8] Available from http://www.ncbi.nlm.nih.gov/books/NBK2510/
66. Scharfman HE. The Neurobiology of Epilepsy. Current Neurology and Neuroscience
Rep. 2007; 7(4): 348–354.
67. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, CrossJH, Boas WE et al.
Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005 – 2009. Epilepsia 2010; 51(4):676–685.
68. Engel J. Report of the ILAE Classification core group. Epilepsia 2006;
47:1558–1568.
69. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE Clinical Guideline 137.
2012. Last modified
Dec2013. [Cited 2014 August 12]. Available from http://www.nice.org.uk/guidance /cg137/resources/guidance-the-epilepsies-the-diagnosis-and-management-of-theepilepsies-in-adults-and-children-in-primary-and-secondary-care-pdf.
70. S J M Smith. EEG in the diagnosis, classification, and management of patients with epilepsy. J Neurol Neurosurg Psychiatry 2005;76:ii2-ii7
71. Aina OF; Danesi MA and Amoo IG (2004). Interictal electroencephalographic findings among persons with epilepsy in Lagos, Nigeria. Nigerian Quarterly Journal of Hospital Medicine; 14 (2): 126-129.
72. Ahmed MH, Obembe A. Electroencephalographic abnormalities in 351 Nigerians with epilepsy. West Afr J Med 1991; 10: 216-221. PubMed.
73. Matuja WB and Ndosi NK. Electroencephalographic findings in epileptic patients in
Tanzania. East African Medical journal 1994; 71(4):236-9.
74. Krumholz S, Wiebe G, Gronseth S, Levisohn P et al. Practice Parameter:
Evaluating an apparent unprovoked first seizure in adults (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the
American Epilepsy Society. Neurology 2007; 69:1996.
75. Beghi E. Treating epilepsy across its different stages. Therapeutic Advances in
Neurological Disorders .2010; 3(2):85-92.
76. Kuzniecky R and Devinsky O. Surgery Insight: surgical management of epilepsy.
Surgery Nature Clinical Practice Neurology 2007; 673-681.
77. Morris III GL, Gloss D, Buchhalter J, Mack KJ, Nickels K and Cynthia Harden, Evidence-based guideline update: Vagus nerve stimulation for the treatment of epilepsy. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013; 81(16): 1453-1459.
78. Hassan.A, Al-Quliti KW, Neurostimulation: A promising therapeutic options for medically refractory epilepsy. Neuroscience (Riyadh) 2014;19(1):4-10.
79. Fisher .s , Velasco A.L, electrical brain stimulation for epilepsy. Nature reviews neurology 10, 261-270(2014)
80. Dwivedi C. Antiepileptic Drugs. American Journal of Pharmaceutical Education
2001; 65(2) :197-202.
81. Kwan P, Sills GJ and Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacology & Therapeutics. 2001; 90: 21– 34.
82. French JA. Treatment with antiepileptic drugs, new and old. Continuum Lifelong
Learning Neurol 2007; 13(4):71–80.
83. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia.2013; 54 :1-13.
84. Sirven J, Sperling MR and Wingerchuk DM. Early versus late antiepileptic drug withdrawal for people with epilepsy in remission. Cochrane Database of Systematic Reviews 2001 ;( 3).
85. Perucca P and Gilliam FG. Adverse effects of antiepileptic drugs. The Lancet Neurol
2012; 9.
86. World Health Organization. International drug monitoring: the role of national centres. World Health Organ Tech Rep Serv1972; 498:1-25.
87. Tatum IV, WO. Antiepileptic drugs: Adverse effects and drug interactions.
Continuum Lifelong LearningNeurol 2010;16(3):134-156.
88. Cramer J.A, Mintzer S, Wheless J and Mattson RH. Adverse effects of antiepileptic drugs: A brief overview of important issues. Expert Rev.
Neurothe 2010; 10(6): 885891.
89. Hill DS, Wlodarczyk BJ, Palacios AM and Finnell RH. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother 2010; 10(6):943-59.
90. Tomson J and Dina B. Teratogenic effects of antiepileptic drugs. The Lancet Neurol
2012;11( 9): 803-13.
91. Harden C L, Hopp J, Ting T Y, Pennell PB, French JA,Hauser WA, et al.
Practice Parameter; Management issues for women with epilepsy --Focus on pregnancy (an evidence-based review): Obstetrical complications and
change in seizure frequency.
Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73:126.
92. Sunmonu T, Ogunrin O, Komolafe MA, Ogunniyi A. Seizure Variables and Cognitive Performance in Patients with Epilepsy. African Journal of Neurological Sciences 2008;
27(2):86-94.
93. Ogunrin O, Adamolekun B and Ogunniyi A. Cognitive Effects of Anti-Epileptic Drugs in Nigerians with Epilepsy. African Journal of Neurological Sciences 2005; 24:18 – 24.
94. Kapoor N, Hamilton RJ: Toxicity, carbamazepine. [Cited 2014 August 8].
Available from [http://www.emedicine.com/emerg/topic77.htm]
95. Internet drug index. Carbamazepine. Cited 2014 August 8]. Available from http://www.medicinenet.com/carbamazepine/article.htm.
96. Powell G, Saunders M, Marson AG. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Cochrane Database Syst
Rev. 2014 Feb 3; 2:CD007124. [cited 2014 Aug. 4] Available from http:/
/www. ncbi.nlm.nih.gov/ pub med /24488654.
97. Neef C, Touw DJ and Stolk LM. Therapeutic Drug Monitoring in Clinical Research
Pharmaceutical Medicine. 2008; 22 (4): 235-244.
98. Suthakaran C and Aditha C. Therapeutic drug monitoring – Concepts, Methodology,
Clinical Applications and Limitations. Health Administrator 2006; XIX (1): 22-26 99. Shan G, Lipton C, Gee SJ and Hammock BD. Immunoassay, biosensors and
other nonchromatographic methods. Handbook of Residue Analytical Methods for Agrochemicals 2002; 623–679.
100. Mycek MJ, Harvey RA, Champe PC. Lippincott illustrated review:
pharmacology 2nd Edition Lippincott Williams and Wilkins copyright 2000.
101. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, and Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: A
randomized trial. Neurology 2004; 62(1): 23-27
102. Canevini MP, De Sarro G, Galimberti CA, Gatti G, Licchetta L, Malerba A et al. On behalf of the SOPHIE Study Group: Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy.
Epilepsia 2010; 51(5):797–804.
103. Specht U, Elsner H, May TW, Schimichowski B, Thorbecke R. Postictal serum levels of antiepileptic drugs for detection of noncompliance. Epilepsy Behaviour 2003; 4(5):487-95.
104. Hussein A, Abdulgalil A, Omer F and Eltoum H. Correlation between Serum Level of Antiepileptic Drugs and their Side Effects. Oman Medical Journal 2010; 25: 17-21.
105. Fadare J, Falade C, Bolaji O and Ogunniyi A. Correlation of the Serum Level of Carbamazepine with Seizure Control and Adverse Drug Reactions among Epileptics in Ibadan, Nigeria. Int. J. Drug Dev. & Res. 2010; 2(4):690-697.
106. Spiller HA, Krenzelok EP and Cookson E. Carbamazepine overdose: a
prospective study of serum levels and toxicity. J Toxicol Clin Toxicol. 1990; 28(4):445- 58.
107. Hojer J, Malmlund HO and Berg A. Clinical features in 28 consecutive cases of laboratory confirmed massive poisoning with carbamazepine alone. J Toxicol Clin Toxicol. 1993; 31(3):449-58.
108. Leslie K. Survey Sampling. New York: John Wiley and Son, Inc.1965.
109. Danesi MA. Classification of the epilepsies: an investigation of 945 patients in a developing country. Epilepsia 1985; 26: 131-136.
110. Ojuawo A, Joiner KT. Childhood epilepsy in Ilorin, Nigeria. East Afr J Med 1997; 74: 72-75.
111. Schmidt D and Schachter S. Drug treatment of epilepsy in adults BMJ 2014;
348: g254
112. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD and Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012;
78(20):1548-54.
113. Brodie, M. Perucca.E, Ryvlin.P, Ben-Menachem.E. Comparison of
levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Neurology 2007;68(6): 402-408
114. Asawavichienjinda T, Sitthi-Amorn C and Tanyanont W. Compliance with treatment of adult epileptics in a rural district of Thailand J Med Assoc Thai. 2003;
86 (1):46-51.
115. Tom Andrew.T, Milini K Baker.G Wieshmann U. Self-reported adverse effects of mono and polytherapy for epilepsy Seizure - European Journal of Epilepsy 2012;
116. Eddy CM, Rickards HE and Cavanna AE. The cognitive impact of antiepileptic drugs. Ther adv neurol disord 2011;4(6):385-407.
117. Perucca P, Jacoby A, Hesdorffer D.C. Adverse antiepileptic drug effects in new-onset pseizures. A case-control study. Neurology 2011; 76(3):273-279.
55.
118. Eichelbaum, M, Bertilsson, L, Lund .L, Palmér.L and Sjoqvist F. Plasma levels of carbamazepine and carbamazepine-10, 11-epoxide during treatment of epilepsy. European Journal of Clinical Pharmacology 1976; 9(5-6): 417-421.
119. Vasudev A, Tripathi KD, Puri V. Correlation of serum and salivary carbamazepine concentration in epileptic patients: implications for therapeutic drug monitoring. Neurology India 2002; 50(1): 60-2.
120. Strandjord RE, Johannessen SI. Single-drug therapy with carbamazepine in patients with epilepsy: serum levels and clinical effect. Epilepsia 1980;
21(6):655-52.
121. Vasudev A, Tripathi KD and Puri V. Association of drug levels &
pharmacokinetics of carbamazepine with seizure control Indian J Med Res.
2000;
112:218-23.
122. Callaghan, N., O’Callaghan N., Duggan B and Feely M. Carbamazepine as a single drug in the treatment of epilepsy, A prospective study of serum levels and seizure control Journal of Neurology, Neurosurgery, and Psychiatry 1978;41:
907912.
123. Gomes MM, Maia FHS, Noe RA. Antiepileptic drug intake adherence. The value of the blood drug level measurement and the clinical approach. Arq Neuropsiquiatr. 1998;56(4):708-13.
124. Panelli.RJ, Kilpatrick.C, Moore.SM, Matkovic.Z, D’Souza WJ and O’Brien TJ.
The Liverpool Adverse Events Profile: Relation to AED Use and Mood Epilepsia
2007; 48(3): 456–463.
125. Gómez-Arias B, Crail-Meléndez D, López-Zapata R, Martínez-Juárez IE.
Severity of anxiety and depression are related to a higher perception of adverse effects of antiepileptic drugs. Seizure. 2012; 21(8):588-94.
126. Viana MC and Andrade LH. Lifetime Prevalence, age and gender distribution and age-of-onset of psychiatric disorders in the São Paulo Metropolitan Area, Brazil: results from the São Paulo Megacity Mental Health Survey. Rev Bras Psiquiatr. 2012; 34(3):249-60.
Appendix 1a
Investigating the relationship between Serum levels of carbamazepine with short term seizure control, adherence and adverse effect profile in patients with epilepsy.
Questionnaire.
1) Surname ………
2) First name………
3) Serial number ……… 4) Hospital number ……….
5) Address ………
6) Telephone number ……….7) Date Of birth: dd/mm/yy………
8) Age ………. 9) Sex: Male Female
10) Marital status: Single Married Separated/divorced 11) Lives: Alone with spouse with parents
others (please specify)………
12) Occupation: student worker specify job ……….. … ….
13) Employment status: employed unemployed
14) Level of education: none primary Secondary tertiary postgraduate 15) Average monthly Income: <N20, 000 20000 - 50000 50 - 100000 >100,000 16) Average cost of drugs monthly………
17) Source of drug funding:Self Spouse Parents Others please specify………
Seizure duration and frequency a) Pretreatment
1) Age at first seizure ……… ………
2) Age at seizure diagnosis ………
3) Description of ictal event ………..
4) Description of post ictal event ………..
5) Was there any aura? ………..
6) How frequent were your seizures? ……. / week…… /month ……….
………… /2months …….. /6months ………/year 7) Do seizures occur at night? Yes No
8) How often do they occur at night? ……. / week…… /month …….. /2months …….. /6months ………/year 9) What are the triggers?
Poor sleep Fatigue Alcohol Febrile illness Menstrual period Excessive sleep Flashing lights
hyperventilation Others please specify ………. b) Post treatment (≥ 9 months)
10) How long have you been on treatment? Please specify………
11) Age at commencement of treatment ………..
12) Have you had any seizures since commencing your drug? Yes…… No……..
13) If yes, would you say: Initially only Occasionally Frequently Sometimes Rarely
14) How frequent are the seizures now? ……. / week…… /month ………. /2months …….. /6months ………/year
15) When was your last seizure? Please specify ………
Drug compliance
16) Medications: Carbamazepine
17) Source of drugs Hospital pharmacy Other pharmacy Local drug shop Market 18) Drug dosage/24hours ……….
20) For carbamazepine. Is it plain or controlled release , please specify ……….
21) How long have you been on the drug? Please specify ..………
22) Are you on any other medication? Yes No If yes specify………..
Do you take herbal drugs? Yes No
23) When was the last dose of antiepileptic drug taken? ………
24) Do you take your drugs everyday as prescribed by your doctor? Yes No 25) If no, how often do you miss your drug? Sometimes Occasionally Never 26) Do you take your drugs only when it is available? Yes No
27) Do you take your drugs only when you feel you are going to have a seizure?